dc.contributor.author | Cingi, Cemal | |
dc.contributor.author | Muluk, Nuray Bayar | |
dc.contributor.author | Hanci, Deniz | |
dc.contributor.author | Ulusoy, Seckin | |
dc.contributor.author | Sahin, Fezan | |
dc.date.accessioned | 2020-06-25T18:15:43Z | |
dc.date.available | 2020-06-25T18:15:43Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | closedAccess | en_US |
dc.identifier.issn | 2042-6976 | |
dc.identifier.issn | 2042-6984 | |
dc.identifier.uri | https://doi.org/10.1002/alr.21447 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12587/6234 | |
dc.description | WOS: 000348915400007 | en_US |
dc.description | PubMed: 25424754 | en_US |
dc.description.abstract | BackgroundAlthough the effectiveness of allergen monotherapy immunotherapy for allergic rhinitis (AR) has been well established by many prior studies, other aspects of immunotherapy are still incompletely documented by high-quality studies. The many published papers describe various results. The aim of the present study was to conduct a meta-analysis on the effectiveness of allergen immunotherapy. MethodsA total of 56 homogeneous studies were included in the analysis. The inclusion criteria used to select articles were as follows: (1) placebo-controlled clinical trials; (2) the use of immunotherapy; (3) participants and/or physicians were or were not blinded to immunotherapy or placebo assignment (single-blinding, double-blinding, or no-blinding studies); and (4) randomization or not of those in the immunotherapy and placebo groups. ResultsBetween 2003 and 2013, 114 placebo-controlled clinical trials were reported in Medline. Studies describing recovery rates in immunotherapy and placebo groups numbered 56. The distribution of such works was homogeneous (heterogeneity chi-square = 16.11; degrees of freedom [df] = 55; p = 1.000). The extent of recovery in immunotherapy groups was 53.671-fold greater than in placebo groups (Mantel-Haenszel [M-H] pooled risk ratio [RR] = 53.671; 95% confidence interval [CI], 36.981 to 77.893; z = 20.96; p < 0.001). ConclusionOur meta-analysis suggests that immunotherapy is associated with a recovery rate 53.671-fold that of placebo. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.isversionof | 10.1002/alr.21447 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | meta-analysis | en_US |
dc.subject | immunotherapy | en_US |
dc.subject | allergic rhinitis | en_US |
dc.subject | placebo-controlled clinical trials | en_US |
dc.subject | recovery rate | en_US |
dc.title | Updating the role played by immunotherapy for allergic rhinitis: meta-analysis | en_US |
dc.type | article | en_US |
dc.contributor.department | Kırıkkale Üniversitesi | en_US |
dc.identifier.volume | 5 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 132 | en_US |
dc.identifier.endpage | 142 | en_US |
dc.relation.journal | International Forum Of Allergy & Rhinology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |